Published in Drug Week, May 14th, 2004
The first traunch closed at $10.9 million. Catalyst Health and Technology Partners led the round, supported by new investors Echelon Ventures and Fletcher Spaght. Original investors from the first traunch include CB Health Ventures, Zero Stage Capital and BioFrontier Partners. The funds will be used to accelerate commercialization of BioTrove's micro- and nanoscale products and services, the Living Chip and Momentum Assay Development and Screening, respectively. The company will also use the funds...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.